GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humanigen Inc (FRA:0KB2) » Definitions » Deferred Policy Acquisition Costs

Humanigen (FRA:0KB2) Deferred Policy Acquisition Costs


View and export this data going back to 2014. Start your Free Trial

What is Humanigen Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Humanigen (FRA:0KB2) Business Description

Industry
Traded in Other Exchanges
Address
830 Morris Turnpike, 4th Floor, Short Hills, NJ, USA, 07078
Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005. It has one segment, which is related to the development of pharmaceutical products.